Arcus Biosciences (RCUS) Common Equity (2016 - 2026)

Arcus Biosciences' Common Equity history runs 11 years deep, the most recent figure standing at $524.0 million for Q1 2026.

• In Q1 2026, Common Equity fell 1.32% year-over-year to $524.0 million; the TTM figure through Mar 2026 stood at $524.0 million (down 1.32% YoY), while the FY2025 annual figure was $631.0 million, up 30.1% from the prior year.
• Common Equity was $524.0 million for Q1 2026 at Arcus Biosciences, down from $631.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $797.0 million in Q1 2022 to a low of $436.0 million in Q3 2025.
• Historically, Common Equity has averaged $594.8 million across 5 years, with a median of $566.0 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Common Equity retreated 29.68% in 2023, then jumped 30.1% in 2025.
• A 5-year view of Common Equity shows it stood at $657.0 million in 2022, then fell by 29.68% to $462.0 million in 2023, then grew by 4.98% to $485.0 million in 2024, then soared by 30.1% to $631.0 million in 2025, then retreated by 16.96% to $524.0 million in 2026.
• The last three Common Equity figures came in at $524.0 million (Q1 2026), $631.0 million (Q4 2025), and $436.0 million (Q3 2025), per Business Quant data.